新型肿瘤内皮特异性标志物在抗血管生成治疗研发中的潜力。

The potential of new tumor endothelium-specific markers for the development of antivascular therapy.

作者信息

Li Ji-Liang, Harris Adrian L

机构信息

Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK.

出版信息

Cancer Cell. 2007 Jun;11(6):478-81. doi: 10.1016/j.ccr.2007.05.004.

DOI:10.1016/j.ccr.2007.05.004

PMID:17560330

Abstract

Angiogenesis is a hallmark of solid tumors, and disruption of tumor vasculature is an active anticancer therapy in some cases. Several proteins expressed on the surface of tumor endothelium have been identified during the last decade. However, due to the expression in both physiological and tumor angiogenesis, only a few targets have been developed for clinical therapeutics. By thorough SAGE analysis of mouse endothelial cells isolated from various normal resting tissues, regenerating liver, and liver-metastasized tumor, Seaman and colleagues in this issue of Cancer Cell have demonstrated organ-specific endothelial markers, physiological angiogenesis endothelial markers, and tumor endothelial markers and revealed striking differences between physiological and pathological angiogenesis.

摘要

血管生成是实体瘤的一个标志，在某些情况下，破坏肿瘤血管系统是一种积极的抗癌疗法。在过去十年中，已经鉴定出几种在肿瘤内皮细胞表面表达的蛋白质。然而，由于这些蛋白质在生理性血管生成和肿瘤血管生成中均有表达，因此仅有少数靶点被开发用于临床治疗。通过对从小鼠各种正常静息组织、再生肝脏和肝转移瘤中分离出的内皮细胞进行全面的基因表达系列分析（SAGE），Seaman及其同事在本期《癌细胞》杂志上展示了器官特异性内皮标志物、生理性血管生成内皮标志物和肿瘤内皮标志物，并揭示了生理性血管生成与病理性血管生成之间的显著差异。